NanoViricides files annual report; NV-387 in Phase II trials
NanoViricides, Inc. (NNVC) has filed its annual report. The company’s broad-spectrum antiviral NV-387 is in Phase II clinical trials.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.